Synaffix
Business Services · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Kloosterstraat 9, Oss, North Brabant, 53...Phone Number
+31 880224505Website
www.synaffix.comRevenue
$6.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Synaffix
Synaffix is a clinical-stage technology provider specializing in enabling top-tier targeted cancer therapeutics through its innovative conjugation technology platform. The company focuses on antibody-drug conjugates (ADCs) and bispecific therapies, allowing firms with antibodies to develop proprietary solutions efficiently. With a strong focus on technology out-licensing, Synaffix collaborates with partners, resulting in multiple best-in-class therapeutic candidates in various stages of development. Their advanced platform facilitates the creation of novel and effective treatments for cancer, targeting significant disease areas in partnership with pharmaceutical companies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Synaffix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Synaffix has new funding data
Check out if Synaffix is spiking on competitors!
Click to see if Synaffix had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Synaffix
Check if Synaffix has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Synaffix launches new products
Synaffix, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Synaffix recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Synaffix as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Synaffix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Synaffix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Synaffix.
Synaffix Tech Stack
A closer look at the technologies used by Synaffix
Most Recent Scoops
Open Position
Open Position
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Promotion
Seeking Replacement
Synaffix News & Media
Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC
License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix's exatecan-based technology with Qurient's CDK7 inhibitor AMSTERDAM and SEONGNAM-SI, South Korea , Sept. 25, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN)...SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113
PRAGUE & AMSTERDAM--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option agreement with Synaffix B.V. (“Synaffix”), a Lonza company (SWX: LONN), to obtain a license to Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs. The exercised option will enable SOTIO to advance two bispecific candidates, designed by its in-house research team, thatSynaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology
License agreement centered around development of a single ADC program Usage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagement AMSTERDAM, Jan. 9, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX:...Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology
AMSTERDAM, BASEL, Switzerland and INGELHEIM, Germany, Jan. 9, 2025 /PRNewswire/ -- Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Synaffix
Sign Up For FreeTo access detailed company insights
Synaffix is a clinical-stage technology provider specializing in enabling top-tier targeted cancer therapeutics through its innovative conjugation technology platform. The company focuses on antibody-drug conjugates (ADCs) and bispecific therapies, allowing firms with antibodies to develop proprietary solutions efficiently. With a strong focus on t... Read More
